Absence of adverse events in healthy individuals using probiotics â analysis of six randomised studies by one study group
In: Beneficial MicrobesSearch for other papers by L. Tapiovaara in
Current site
Google Scholar
Search for other papers by L. Lehtoranta in
Current site
Google Scholar
Search for other papers by T. Poussa in
Current site
Google Scholar
Search for other papers by H. Mäkivuokko in
Current site
Google Scholar
Search for other papers by R. Korpela in
Current site
Google Scholar
Search for other papers by A. Pitkäranta in
Current site
Google Scholar
Consumption of live bacteria as probiotic supplements is increasing. There is, however, a lack of information on the safety of ingested probiotics. The main objective of this study was to investigate the adverse events (AEs) of specific probiotics (Lactobacillus rhamnosus GG (LGG) alone or LGG in combination with L. rhamnosus Lc705, Propionibacterium freudenreichii JS, Bifidobacterium lactis BB12, or Bifidobacterium breve 99) studied in six of our study groupsâ clinical trials, by analysing individual participant data. A secondary objective was to study AEs associated with the consumed probiotic species and mixtures in three specific categories; âgastrointestinal disordersâ, ârespiratory, thoracic and mediastinal disordersâ and âinfections and infestationsâ. Six randomised, double-blind, placebo-controlled clinical studies by our study group were included in this AE analysis (study population n=1,909). All AE data were classified according to the National Cancer Instituteâs Common Terminology Criteria for Adverse Events (CTCAE) v4.0. From the 26 CTCAE System Organ Classes, we identified AEs in 20 classes among 1,909 subjects. Probiotic ingestion did not result in statistically significant differences in AEs in different groups, when compared to placebo. A subgroup analysis of gastrointestinal, respiratory, thoracic and mediastinal disorders, infections and infestations, found no differences between the intervention groups or for different probiotic combinations (risk ratio (RR) = 0.97, 95% confidence interval (CI): 0.93-1.02, P=0.30; RR=0.99, 95% CI: 0.97-1.01, P=0.35; RR=0.99, 95% CI: 0.93-1.06, P=0.62, respectively). As a conclusion, ingestion of probiotic supplementations containing LGG alone, or LGG in combination with L. rhamnosus Lc705, P. freudenreichii JS, B. breve 99, or B. lactis BB12 did not seem to cause AEs in young and elderly subjects in this analysis.
Purchase
Buy instant access (PDF download and unlimited online access):
Institutional Login
Log in with Open Athens, Shibboleth, or your institutional credentials
Personal login
Log in with your brill.com account
-
Besselink, M.G., Van Santvoort, H.C., Buskens, E, Boermeester, M.A., Van Goor, H., Timmerman, H.M., Nieuwenhuijs, V.B., Bollen, T.L., Van Ramshorst, B., Witteman, B.J., Rosman, C., Ploeg, R.J., Brink, M.A., Schaapherder, A.F., Dejong, C.H., Wahab, P.J., Van Laarhoven, C.J., Van der Harst, E., Van Eijck, C.H., Cuesta, M.A., Akkermans, L.M. and Gooszen, H.G., 2008. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. The Lancet 371: 651-659.
'Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial ' () 371 The Lancet : 651 -659.
-
Didari, T., Solki, S., Mozaffari, S., Nikfar, S. and Abdollahi, M., 2014. A systematic review of the safety of probiotics. Expert Opinion on Drug Safety 13: 227-239.
'A systematic review of the safety of probiotics ' () 13 Expert Opinion on Drug Safety : 227 -239.
-
DiRienzo, D.B., 2014. Effect of probiotics on biomarkers of cardiovascular disease: implications for heart-healthy diets. Nutrition Reviews 72: 18-29.
'Effect of probiotics on biomarkers of cardiovascular disease: implications for heart-healthy diets ' () 72 Nutrition Reviews : 18 -29.
-
Food and Agriculture Organization of the United Nations/World Health Organization (FAO/WHO), 2002. Guidelines for the evaluation of probiotics in food. Report of a Joint FAO/WHO working group on drafting guidelines for the evaluation of probiotics in food. Available at: http://tinyurl.com/ou88oa2.
-
Hatakka, K., Ahola, A.J., Yli-Knuuttila, H., Richardson, M., Poussa, T., Meurman, J.H. and Korpela R., 2007a. Probiotics reduce the prevalence of oral Candida in the elderly â a randomized controlled trial. Journal of Dental Research 86: 125-130.
'Probiotics reduce the prevalence of oral Candida in the elderly â a randomized controlled trial ' () 86 Journal of Dental Research : 125 -130.
-
Hatakka, K., Savilahti, E., Pönkä, A., Meurman, J.H., Poussa, T., Näse, L., Saxelin, M. and Korpela, R., 2001. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. British Medical Journal 322: 1327-1329.
'Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial ' () 322 British Medical Journal : 1327 -1329.
-
Hatakka, K., 2007. Probiotics in the prevention of clinical manifestations of common infectious diseases in children and in the elderly. PhD thesis, University of Helsinki, Helsinki, Finland. Available at: http://ethesis.helsinki.fi.
-
Hatakka, K., Blomgren, K., Pohjavuori, S., Kaijalainen, T., Poussa, T., Leinonen, M., Korpela, R. and Pitkäranta, A., 2007b. Treatment of acute otitis media with probiotics in otitis-prone children-a double-blind, placebo-controlled randomised study. Clinical Nutrition 26: 314-321.
'Treatment of acute otitis media with probiotics in otitis-prone children-a double-blind, placebo-controlled randomised study ' () 26 Clinical Nutrition : 314 -321.
-
Hempel, S., Newberry, S., Ruelaz, A., Wang, Z., Miles, J., Suttorp, M., Johnsen, B., Shanman, R., Slusser, W., Fu, N., Smith, A., Roth, B., Polak, J., Motala, A., Perry, T. and Shekelle, P., 2011. Safety of probiotics used to reduce risk and prevent or treat disease. Agency for Healthcare Research and Quality. Available at http://www.ncbi.nlm.nih.gov/books/NBK56091/.
-
Hill, C., Guarner, F., Reid, G., Gibson, G.R., Merenstein, D.J., Pot, B., Morelli, L., Canani, R.B., Flint, H.J., Salminen, S., Calder, P.C. and Sanders, M.E., 2014. Expert consensus document: the international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology and Hepatology 11: 506-514.
'Expert consensus document: the international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic ' () 11 Nature Reviews Gastroenterology and Hepatology : 506 -514.
-
Huang, J.S., Bousvaros, A., Lee, J.W., Diaz, A. and Davidson, E.J., 2002. Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Digestive Diseases and Sciences 47: 2625-2634.
'Efficacy of probiotic use in acute diarrhea in children: a meta-analysis ' () 47 Digestive Diseases and Sciences : 2625 -2634.
-
Kajander, K., Myllyluoma, E., RajiliÄ-StojanoviÄ, M., Kyrönpalo, S., Rasmussen, M., Järvenpää, S., Zoetendal, E.G., De Vos, W.M., Vapaatalo, H. and Korpela, R., 2008. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Alimentary Pharmacology and Therapeutics 27: 48-57.
'Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota ' () 27 Alimentary Pharmacology and Therapeutics : 48 -57.
-
Kalliomäki, M., Salminen, S., Poussa, T., Arvilommi, H. and Isolauri, E., 2003. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. The Lancet 361: 1869-1871.
'Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial ' () 361 The Lancet : 1869 -1871.
-
Kumpu, M., Kekkonen, R.A., Kautiainen, H., Järvenpää, S., Kristo, A., Huovinen, P., Pitkäranta, A., Korpela, R. and Hatakka, K., 2012. Milk containing probiotic Lactobacillus rhamnosus GG and respiratory illness in children: a randomized, double-blind, placebo-controlled trial. European Journal of Clinical Nutrition 66: 1020-1023.
'Milk containing probiotic Lactobacillus rhamnosus GG and respiratory illness in children: a randomized, double-blind, placebo-controlled trial ' () 66 European Journal of Clinical Nutrition : 1020 -1023.
-
Land, M.H., Rouster-Stevens, K., Woods, C.R., Cannon, M.L., Cnota, J. and Shetty, A.K., 2005. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 115: 178-181.
'Lactobacillus sepsis associated with probiotic therapy ' () 115 Pediatrics : 178 -181.
-
Lehtoranta, L., Kalima, K., He, L., Lappalainen, M., Roivainen, M., Närkiö, M., Mäkelä, M., Sitonen, S., Korpela, R. and Pitkäranta, A., 2014. Specific probiotics and virological findings in symptomatic conscripts attending military service in Finland. Journal of Clinical Virology 60: 276-281.
'Specific probiotics and virological findings in symptomatic conscripts attending military service in Finland ' () 60 Journal of Clinical Virology : 276 -281.
-
Lehtoranta, L., Söderlund-Venermo, M., Nokso-Koivisto, J., Toivola, H., Blomgren, K., Hatakka, K., Poussa, T., Korpela, R. and Pitkäranta, A., 2012. Human bocavirus in the nasopharynx of otitis-prone children. International Journal of Pediatric Otorhinolaryngology 76: 206-211.
'Human bocavirus in the nasopharynx of otitis-prone children ' () 76 International Journal of Pediatric Otorhinolaryngology : 206 -211.
-
Liu, S., Hu, P., Du, X., Zhou, T. and Pei, X., 2013. Lactobacillus rhamnosus GG supplementation for preventing respiratory infections in children: a meta-analysis of randomized, placebo-controlled trials. Indian Pediatrics 50: 377-381.
'Lactobacillus rhamnosus GG supplementation for preventing respiratory infections in children: a meta-analysis of randomized, placebo-controlled trials ' () 50 Indian Pediatrics : 377 -381.
-
Luoto, R., Ruuskanen, O., Waris, M., Kalliomäki, M., Salminen, S. and Isolauri, E., 2014. Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: A randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology 133: 405-413.
'Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: A randomized, placebo-controlled trial ' () 133 Journal of Allergy and Clinical Immunology : 405 -413.
-
Luoto, R., Isolauri, E. and Lehtonen, L., 2010. Safety of Lactobacillus GG probiotic in infants with very low birth weight: twelve years of experience. Clinical Infectious Diseases 50: 1327-1328.
'Safety of Lactobacillus GG probiotic in infants with very low birth weight: twelve years of experience ' () 50 Clinical Infectious Diseases : 1327 -1328.
-
Mackay, A.D., Taylor, M.B., Kibbler, C.C. and Hamilton-Miller, J.M., 1999. Lactobacillus endocarditis caused by a probiotic organism. Clinical Microbiology and Infection 5: 290-292.
'Lactobacillus endocarditis caused by a probiotic organism ' () 5 Clinical Microbiology and Infection : 290 -292.
-
Redman, M.G., Ward, E.J. and Phillips, R.S., 2014. The efficacy and safety of probiotics in people with cancer: a systematic review. Annals of Oncology 25: 1919-1929.
'The efficacy and safety of probiotics in people with cancer: a systematic review ' () 25 Annals of Oncology : 1919 -1929.
-
Salminen, M.K., Tynkkynen, S., Rautelin, H., Saxelin, M., Vaara, M., Ruutu, P., Sarna, S., Valtonen, V. and Järvinen, A., 2002. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clinical Infectious Diseases 35: 1155-1160.
'Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland ' () 35 Clinical Infectious Diseases : 1155 -1160.
-
Sanders, M.E., Akkermans, L.M., Haller, D., Hammerman, C., Heimbach, J., Hörmannsperger, G., Huys, G., Levy, D.D., Lutgendorff, F., Mack, D., Phothirath, P., Solano-Aguilar, G. and Vaughan, E., 2010. Safety assessment of probiotics for human use. Gut Microbes 1: 164-185.
'Safety assessment of probiotics for human use ' () 1 Gut Microbes : 164 -185.
-
Siró, I, Kápolna, E, Kápolna, B. and Lugasi, A., 2008. Functional food. Product development, marketing and consumer acceptance â a review. Appetite 51: 456-467.
'Functional food. Product development, marketing and consumer acceptance â a review ' () 51 Appetite : 456 -467.
-
Szajewska, H. and Chmielewska, A., 2013. Growth of infants fed formula supplemented with Bifidobacterium lactis Bb12 or Lactobacillus GG: a systematic review of randomized controlled trials. BMC Pediatrics 13: 185-195.
'Growth of infants fed formula supplemented with Bifidobacterium lactis Bb12 or Lactobacillus GG: a systematic review of randomized controlled trials ' () 13 BMC Pediatrics : 185 -195.
-
Taipale, T., Pienihäkkinen, K., Isolauri, E., Larsen, C., Brockmann, E., Alanen, P., Jokela, J. and Söderling, E., 2011. Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy. British Journal of Nutrition 105: 409-416.
'Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy ' () 105 British Journal of Nutrition : 409 -416.
-
US Food and Drug Administration (US-FDA), 2009. Generally recognized as safe (GRAS) notices. Available at: http://www.accessdata.fda.gov/scripts/fdcc/?set=GRASNotices.
-
Van den Nieuwboer, M., Brummer, R.J., Guarner, F., Morelli, L., Cabana, M. and Claasen, E., 2015a. The administration of probiotics and synbiotics in immune compromised adults: is it safe? Beneficial Microbes 6: 3-17.
'The administration of probiotics and synbiotics in immune compromised adults: is it safe? ' () 6 Beneficial Microbes : 3 -17.
-
Van den Nieuwboer, M., Brummer, R.J., Guarner, F., Morelli, L., Cabana, M. and Claassen, E., 2015b. Safety of probiotics and synbiotics in children under 18 years of age. Beneficial Microbes 6: 615-630.
'Safety of probiotics and synbiotics in children under 18 years of age ' () 6 Beneficial Microbes : 615 -630.
-
Van den Nieuwboer, M, Claassen, E., Morelli, L., Guarner, F. and Brummer, R.J., 2014. Probiotic and synbiotic safety in infants under two years of age. Beneficial Microbes 5: 45-60.
'Probiotic and synbiotic safety in infants under two years of age ' () 5 Beneficial Microbes : 45 -60.
-
Whelan, K. and Myers, C.E., 2010. Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials. American Journal of Clinical Nutrition 91: 687-703.
'Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials ' () 91 American Journal of Clinical Nutrition : 687 -703.
| All Time | Past 365 days | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 683 | 229 | 19 |
| Full Text Views | 10 | 0 | 0 |
| PDF Views & Downloads | 8 | 0 | 0 |
Absence of adverse events in healthy individuals using probiotics â analysis of six randomised studies by one study group
In: Beneficial MicrobesSearch for other papers by L. Tapiovaara in
Current site
Google Scholar
PubMed
Search for other papers by L. Lehtoranta in
Current site
Google Scholar
PubMed
Search for other papers by T. Poussa in
Current site
Google Scholar
PubMed
Search for other papers by H. Mäkivuokko in
Current site
Google Scholar
PubMed
Search for other papers by R. Korpela in
Current site
Google Scholar
PubMed
Search for other papers by A. Pitkäranta in
Current site
Google Scholar
PubMed
Consumption of live bacteria as probiotic supplements is increasing. There is, however, a lack of information on the safety of ingested probiotics. The main objective of this study was to investigate the adverse events (AEs) of specific probiotics (Lactobacillus rhamnosus GG (LGG) alone or LGG in combination with L. rhamnosus Lc705, Propionibacterium freudenreichii JS, Bifidobacterium lactis BB12, or Bifidobacterium breve 99) studied in six of our study groupsâ clinical trials, by analysing individual participant data. A secondary objective was to study AEs associated with the consumed probiotic species and mixtures in three specific categories; âgastrointestinal disordersâ, ârespiratory, thoracic and mediastinal disordersâ and âinfections and infestationsâ. Six randomised, double-blind, placebo-controlled clinical studies by our study group were included in this AE analysis (study population n=1,909). All AE data were classified according to the National Cancer Instituteâs Common Terminology Criteria for Adverse Events (CTCAE) v4.0. From the 26 CTCAE System Organ Classes, we identified AEs in 20 classes among 1,909 subjects. Probiotic ingestion did not result in statistically significant differences in AEs in different groups, when compared to placebo. A subgroup analysis of gastrointestinal, respiratory, thoracic and mediastinal disorders, infections and infestations, found no differences between the intervention groups or for different probiotic combinations (risk ratio (RR) = 0.97, 95% confidence interval (CI): 0.93-1.02, P=0.30; RR=0.99, 95% CI: 0.97-1.01, P=0.35; RR=0.99, 95% CI: 0.93-1.06, P=0.62, respectively). As a conclusion, ingestion of probiotic supplementations containing LGG alone, or LGG in combination with L. rhamnosus Lc705, P. freudenreichii JS, B. breve 99, or B. lactis BB12 did not seem to cause AEs in young and elderly subjects in this analysis.
| All Time | Past 365 days | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 683 | 229 | 19 |
| Full Text Views | 10 | 0 | 0 |
| PDF Views & Downloads | 8 | 0 | 0 |
